Seer (NASDAQ:SEER) Trading Down 0.9% - Time to Sell?

Key Points

• Seer, Inc. (NASDAQ:SEER) shares fell 0.9% to close at $2.18, with a trading volume decrease of 12% from the average volume.
• The company reported a quarterly earnings surprise, achieving revenues of $4.21 million, surpassing the expected $3.25 million, and EPS of ($0.34), beating estimates of ($0.37).
• Insider activity included Director Dipchand Nishar selling 30,253 shares at $2.08, decreasing his ownership by 38.07%, highlighting a significant reduction in insider holdings.

Seer, Inc. (NASDAQ:SEER - Get Free Report)'s stock price traded down 0.9% on Tuesday . The stock traded as low as $2.12 and last traded at $2.18. 82,025 shares changed hands during mid-day trading, a decline of 12% from the average session volume of 92,871 shares. The stock had previously closed at $2.20.

Seer Stock Performance

The stock has a market capitalization of $128.34 million, a price-to-earnings ratio of -1.55 and a beta of 1.57. The business's 50 day simple moving average is $2.11 and its 200-day simple moving average is $2.09.

Seer (NASDAQ:SEER - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.03. Seer had a negative return on equity of 24.69% and a negative net margin of 560.90%. The company had revenue of $4.21 million for the quarter, compared to analysts' expectations of $3.25 million. As a group, sell-side analysts expect that Seer, Inc. will post -1.42 EPS for the current year.

Insider Activity at Seer

In related news, Director Dipchand Nishar sold 30,253 shares of the company's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $2.08, for a total value of $62,926.24. Following the completion of the sale, the director owned 49,204 shares of the company's stock, valued at $102,344.32. This represents a 38.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 11.28% of the company's stock.

Hedge Funds Weigh In On Seer

Several large investors have recently bought and sold shares of SEER. Corient Private Wealth LLC boosted its holdings in shares of Seer by 66.0% in the fourth quarter. Corient Private Wealth LLC now owns 33,200 shares of the company's stock valued at $77,000 after acquiring an additional 13,200 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Seer by 27.0% during the 4th quarter. Renaissance Technologies LLC now owns 843,700 shares of the company's stock valued at $1,949,000 after purchasing an additional 179,568 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Seer by 4.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 127,711 shares of the company's stock valued at $295,000 after purchasing an additional 5,000 shares in the last quarter. Fuller & Thaler Asset Management Inc. acquired a new position in shares of Seer during the 4th quarter valued at $179,000. Finally, Northern Trust Corp lifted its holdings in shares of Seer by 48.7% in the fourth quarter. Northern Trust Corp now owns 155,617 shares of the company's stock valued at $359,000 after buying an additional 50,992 shares during the period. Institutional investors and hedge funds own 75.20% of the company's stock.

Seer Company Profile

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.